Key Takeaways
- Revenue hit by transit timing, not demand: Contrast Media revenue fell 17% QoQ solely because transit times doubled to 60 days, leaving 45% of production unrecognized; those goods will book in subsequent quarters.
- PI-API phasing masks strong H1: PI-API dropped 80% QoQ on order phasing, but H1 grew 113% YoY to ₹255 crore, driven by the cardiovascular intermediate.
- Gross margin swing is a CMI accounting artifact: Gross margin jumped from 48% to 65% QoQ because overhead was apportioned only to the 55% of production sold; management says annualized margins are stable.
- Pipeline conviction is rising: The company is tracking ~20 RFPs, with 6 high-conviction Phase-III leads in chronic disease, and a new Sweetener has been approved by a key customer.
- What to watch next quarter: Whether the 45% of CMI production stuck in transit reverses and books in Q3, the pace of Mahad commissioning in H2, and any commercial validation milestone for the new iodinated intermediate.
Contrast Media: The Transit Distortion
- Revenue recognition lag, not a demand problem: Q2 revenue of ₹81 crore reflects only 55% of production because transit time to customers increased from 35-40 days to 60 days due to Red Sea rerouting. Dispatches and production were much higher. The unrecognized goods in transit will be recognized in the subsequent quarter.
- Gross margin volatility is CMI-specific: Because overhead is apportioned only to the quantity sold, quarters with low off-take produce exaggerated margin swings. In PI-API, delivery is Ex Works so this variance does not occur. Management says taking a half-yearly or annual number gives a good representation of the margin profile.
- The opening cutoff amplified the effect: Opening transit inventory was very low due to customer off-take patterns, so a larger portion of produced goods ended the quarter in transit. If opening and closing transit were identical, the issue would not arise. Q1 did not have as much in transit. This is partially a one-off situation.
- 2H outlook is stable: Based on customer forecasts, the CMI business is "pretty stable" and could see a repeat of last year's trend.
- Two needle movers in the 12-18 month pipeline: An NCE molecule for the MRI space is growing extremely well, and an iodinated intermediate for contrast media has capacity ready with product under validation.
Shiven Arora: "While quarterly variations are natural, our medium to long term visibility is strong, fueled by order book momentum, customer lock-ins, new validations and upcoming commercial milestones."
PI-API & the Cardiovascular Intermediate
- Q2 phasing, H1 strength: PI-API revenue fell 80% QoQ to ₹42 crore due to order phasing, but H1 grew 113% YoY to ₹255 crore. The cardiovascular drug intermediate is the primary driver.
- Channel inventory destocking is a launch dynamic: When the molecule launches in new markets, including Japan, launch quantities create channel inventory that temporarily affects offtake.
- Bempedoic Acid is patent-protected till 2031: It is the only oral product approved for hypercholesterolemia, with additional indications being approved and new markets opening. The triple combination could be a "game changer."
- Capacity built with a 5-year view: Ramp-up could be accelerated or delayed by 12-18 months. The company works very closely with customers; capacity is built in anticipation of orders, not speculatively.
- Full-year view held: The company continues to hold its earlier statement about slight growth for the full year based on the order book, despite the Q2 phasing.
V.K. Singh: "The molecule is growing very fast. So, there is space for us and for any other competitor. The other thing is that we are protected with long-term contracts. And if you see the data, the primary source of supply is us, besides the opportunity is extremely big and the triple combination could be a game changer."
Chronic Disease Pipeline: The Next Leg
- 10-12 products in the chronic disease category: 2-3 candidates are very scalable. The company is tracking RFPs and signing up with very large innovator companies. Extra capacity is being built for this vertical in both Mahad and Vizag.
- Three late-stage Onco and CNS candidates: High conviction, with extremely good data and extremely large customers. Commercialization is targeted for FY '27.
- Peptide fragments for GLP-1s: The plan is only for fragments, not full peptides. The company is engaging with clients and signing supply contracts. A new R&D center in Hyderabad (₹40 crore) will include peptide intermediates, biocatalysts, and immobilized catalysts.
- Meaningful contribution from other molecules: Expected in FY '27 and beyond.
Sweeteners: The Replication Play
- New Sweetener approved by key customer: Global market size of ~₹100 crore with high per kg realization. An anchor customer has been tied up, but a range of customers is on the radar.
- The Saccharin playbook: The company aims to capture 10% of the world market, replicating its Saccharin strategy. Meaningful volumes will come from the Vizag facility; in the interim, smaller quantities will be supplied from multi-purpose plants.
- Off-take agreements are long-term: Commitments in the CMI and Sweetener segments are long-term in nature. The company funds CAPEX from internal accruals given its strong net cash position.
Shiven Arora: "What we have done in Saccharin, we want to replicate the same strategy. And what we had done in Saccharin, we were trying to capture 10% of the world market. Over here also, our endeavor would be to reach to that 10% in a long-term vision."
Capacity Build-Out: Mahad & Vizag
- Mahad backward integration on track for H2 FY26: The facility migrates to flow synthesis for KSMs for CMI products, a first for the company. CAPEX has been increased from ₹250 crore to ~₹300 crore due to automation.
- Margin expansion will be gradual: Spread over the next few quarters, focused on building stability and resilience. The company will continue to buy some material from existing partners for supply chain resilience.
- Vizag Phase-I by FY '28: The 103-acre site has master planning complete; groundbreaking is expected in the coming quarter. Phase-I targets capacity for contrast media and artificial sweeteners. Subsequent phases come on stream in FY '29 and beyond.
- Total capacity addition of 1,000 KL over 2-3 years: Greenfield costs will be mostly capitalized, with no incremental cost till commercialization. Some R&D expenditure and senior management expansion will increase operating expenses, but given growth in the next 18-24 months, similar margins can be sustained.
- New iodinated intermediate going commercial in Q4 FY26: Customer outlook is encouraging. Iodinated ABA HCL and an MRI product have both started commercial supply.
V.K. Singh: "With this plant going on stream, we strengthen our position as a credible and leading global supplier of CMI to all the leading innovator companies in this segment... we achieve not only strategic independence but also insulate the business from significant volatility that we have in key raw material prices."
Margins & Financials
- EBITDA margin stable at 33%: Operating expenses were more or less stable QoQ. PAT margin rose 6% sequentially to 32%, driven by other income of ₹24 crore from exchange gains and short-term investments.
- Full-year EBITDA target of ~35%: Management endeavors to maintain about 35% for the full year.
- Annualized gross margin stability: With the current portfolio, on an annualized basis gross margin will be more or less stable. Quarterly volatility could continue depending on customer order pickup, but this is specific to the CMI segment.
- Management declined segment-level profitability disclosure: When asked about the EBITDA impact of elongated transit timelines (an analyst estimated ~₹25 crore), management declined to discuss profitability by segment or by molecule. Segment-wise gross margins are also not prepared.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Mahad backward integration commissioning | Site to go live; flow synthesis for CMI KSMs | H2 FY26 |
| New iodinated intermediate commercialization | Commercial supply begins | Q4 FY26 |
| Three Onco/CNS late-stage candidates | Commercialization targeted | FY '27 |
| Other chronic molecules meaningful contribution | Revenue contribution begins | FY '27 and beyond |
| Vizag Phase-I completion | Capacity for contrast media and sweeteners | FY '28 |
| Total capacity addition | Additional 1,000 KL across Mahad and Vizag | 2-3 years |
| Full-year EBITDA | Endeavor to maintain ~35% | FY26 |
| PI-API full-year growth | Slight growth based on order book | FY26 |
| New Sweetener long-term market share | 10% of world market | Long-term (no date) |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue from operations | ₹165 cr, down 54% QoQ and 21% YoY |
| H1 FY26 revenue from operations | ₹518 cr, up 40% YoY |
| EBITDA | ₹60.1 cr, 36% margin, up 14% YoY |
| EBITDA margin | 33%, down 1 ppt sequentially |
| H1 FY26 EBITDA | ₹182 cr, 35% margin, up 41% YoY |
| PAT | ₹43.2 cr, 26% margin |
| PAT margin | 32%, up 6 ppt sequentially |
| H1 FY26 PAT | ₹134.2 cr, up 36% YoY |
| Other income | ₹24 cr, primarily exchange gain and return on short-term investments |
| Gross margin | 65%, versus 48% in Q1 FY26 |
| H1 FY26 gross margin | 54% |
| Contrast Media revenue | ₹81 cr, down 17% QoQ |
| Contrast Media H1 FY26 revenue | ₹178 cr, flat YoY |
| Pharma Intermediates and API revenue | ₹42 cr, down 80% QoQ |
| Pharma Intermediates and API H1 FY26 revenue | ₹255 cr, up 113% YoY |
| High-intensity Sweeteners growth | 7% sequential growth in Q2 |
| High-intensity Sweeteners H1 FY26 growth | 3% YoY |
| Cash and liquid investments | ₹341 cr, debt-free |
| H1 FY26 CAPEX incurred | ~₹135 cr |
| Annualized capacity utilization | 60%–65%, expected to stay in that range |
| US revenue share | Less than 5% of overall revenues |
| Bempedoic Acid molecule growth | 10%–15% QoQ in the last quarter |
| Transit time for Contrast Media shipments | 60 days, up from 35–40 days previously |
| Share of Q2 Contrast Media production recognized as sale | 55%, remainder in transit to be recognized in subsequent quarter |